Niinimäki Maarit, Mentula Maarit, Jahangiri Reetta, Männistö Jaana, Haverinen Annina, Heikinheimo Oskari
Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University Hospital of Oulu and University of Oulu, Oulu, Finland.
Department of Obstetrics and Gynecology, University of Helsinki, and Helsinki University Hospital/Kätilöopisto Hospital, Helsinki, Finland.
PLoS One. 2017 Jul 28;12(7):e0182198. doi: 10.1371/journal.pone.0182198. eCollection 2017.
Research on the treatment of second-trimester miscarriages is scarce. We studied the outcomes, and the factors associated with adverse events and need for hospital resources in the medical treatment of second-trimester miscarriage.
In these retrospective analyses we studied women treated for spontaneous fetal miscarriage with misoprostol-only (n = 24) or mifepristone and misoprostol (n = 177) in duration of gestation 12+1-21+6. Primary outcomes were the risk factors for surgical evacuation and excessive bleeding. Secondary outcomes were total misoprostol dose, time to expulsion and the length of hospital stay.
History of surgical evacuation of the uterus increased the risk of surgical evacuation (p = 0.027). Excessive bleeding was not associated with any of the studied variables. More misoprostol was needed when the duration of gestation exceeded 17+0 weeks (p = 0.036). In multivariate analysis the time to fetal expulsion was shorter in women with history of 1-2 deliveries (hazard ratio [HR] 1.49, 95% confidence interval [CI]; 1.07-2.07), ≥3 deliveries (HR 1.63, 95% CI; 1.11-2.38) and with a two-day interval between mifepristone-misoprostol administration (HR 1.71, 95% CI; 1.05-2.81). Patients with symptoms (i.e. uterine bleeding or pain) at baseline had longer hospital stay (HR 0.66, 95% CI; 0.47-0.92).
The factors affecting the outcomes of medical treatment of second-trimester fetal miscarriage are similar to those of second-trimester induced abortion. Two-day interval between mifepristone-misoprostol administration might decrease the time to fetal expulsion and the need of hospital resources.
关于孕中期流产治疗的研究较少。我们研究了孕中期流产药物治疗的结局,以及与不良事件和医院资源需求相关的因素。
在这些回顾性分析中,我们研究了妊娠12 + 1至21 + 6周期间仅使用米索前列醇(n = 24)或米非司酮与米索前列醇联合治疗(n = 177)自然流产的女性。主要结局是手术清宫和出血过多的危险因素。次要结局是米索前列醇总剂量、排出时间和住院时间。
子宫手术清宫史增加了手术清宫的风险(p = 0.027)。出血过多与任何研究变量均无关联。妊娠超过17 + 0周时需要更多的米索前列醇(p = 0.036)。多因素分析显示,有1 - 2次分娩史的女性胎儿排出时间较短(风险比[HR] 1.49,95%置信区间[CI];1.07 - 2.07),有≥3次分娩史的女性(HR 1.63,95% CI;1.11 - 2.38)以及米非司酮 - 米索前列醇给药间隔为两天的女性(HR 1.71,95% CI;1.05 - 2.81)。基线时有症状(即子宫出血或疼痛)的患者住院时间更长(HR 0.66,95% CI;0.47 - 0.92)。
影响孕中期胎儿流产药物治疗结局的因素与孕中期人工流产相似。米非司酮 - 米索前列醇给药间隔两天可能会缩短胎儿排出时间并减少医院资源需求。